11:30 am – 12:30 pm Friday, October 29

Joint Topic: Anticoagulation Therapy Anticoagulation Alphabet Soup: VKAs, LMWHs, and DOACs (214-1)

Treatment of thrombosis in pediatric patients presents many challenges. Thrombosis in pediatric patients has a wide range of etiologies, and researchers lack consensus about duration of therapy based on the thrombosis location and the presence of risk factors. Most patients under 18 years of age are treated with either parenteral low-molecular-weight heparins (LMWH) or vitamin K antagonists (VKAs).

Read more...
Speaker:
Ashleigh Brown, BSN RN CPN CPHON®
CNE Hours
1
RX Hours
0.25
2:15 – 3:15 pm Saturday, October 30

Treating Smarter, Not Harder: Abandoning Intensification and Replacing with Immunotherapy for Patients with Down Syndrome and B-ALL (C234)

coglogoChildren with Down syndrome (DS) have a striking predisposition for developing acute leukemia, with a 40-fold increased risk of developing acute lymphoblastic leukemia (ALL) compared to non-DS patients (Wadhwa et al, 2017). Approximately 3% of children with ALL have DS, and these children have inferior outcomes and higher rates of treatment-related mortality (TRM) and are at greater risk of relapse (Buitenkamp et al., 2014).

Read more...
5:00 – 6:00 pm Thursday, October 28

Lighting the Way in COG with MATCH: Targeted Therapies in Pediatric CNS Tumors (C211)

coglogoPediatric MATCH (Molecular Analysis for Therapy Choice) is a joint effort between the National Cancer Institute (NCI) and Children’s Oncology Group (COG) matching targeted therapies to specific tumor genomic sequencing in patients with relapsed or refractory solid tumors, non-Hodgkin lymphomas, brain tumors, and histiocytic disorders.

Read more...
3:30 – 4:30 pm Friday, October 29

Paper Presentation: Long Term (or Chronic) Supportive Care — Long-term Anticoagulation in Children Utilizing Fondaparinux-A Single Pediatric Center Experience (222-3)

Fondaparinux is a synthetic, subcutaneously administered heparinoid that selectively inhibits activated factor X. Pediatric studies of fondaparinux have shown safety and efficacy profiles for the treatment of venous thromboembolism that was similar to standard pediatric anticoagulants.

Read more...
3:30 – 4:30 pm Friday, October 29

Paper Presentation: Long Term (or Chronic) Supportive Care — Individualized Pain Plans in Managing Pain in Patients with Sickle Cell Disease (222-2)

Vaso-occlusive crisis (VOC) is the leading cause of hospital admissions in pediatric patients with sickle cell disease (SCD). Achieving the maximum opioid dose earlier in the admission is associated with shorter lengths of stays, allowing children suffering from SCD to spend less time in the hospital and decreasing their risk for depression and other long-term hospital-associated complications.

Read more...
2:15 – 3:15 pm Saturday, October 30

Perspectives on supporting schooling for children with cancer: Findings from two PCORI Engagement Projects (230)

Education is an important social determinant of health, and treatment for childhood cancers can result in long-term neurocognitive effects (deficits in processing speed, working memory, executive function, and attention), which are associated with reduced educational attainment, employment, and ability to live independently.

Read more...
Subscribe to this RSS feed